Viatris (VTRS) Long-Term Investments (2020)
Viatris' (VTRS) quarterly Long-Term Investments came in at $25.0 million in Q4 2020.
Viatris (VTRS) Long-Term Investments (2020) Analysis & Trends
Viatris' Long-Term Investments history runs 1 years deep, the most recent figure standing at $25.0 million for Q4 2020.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $25.0 million in Q4 2020; TTM through Dec 2020 was $25.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $25.0 million, changed N/A from the prior year.
- Long-Term Investments held at $25.0 million in Q4 2020 per VTRS's latest filing.
- Across five years, Long-Term Investments topped out at $25.0 million in Q4 2020 and bottomed at $25.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 25.00 Mn |